样式: 排序: IF: - GO 导出 标记为已读
-
How can we improve the successful identification of patients suitable for CAR-T cell therapy? Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-09-11 Youqin Feng, Longyuan Wu, Tianning Gu, Yongxian Hu, He Huang
In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies. However, the id...
-
Research advancement in fluid biomarkers for Parkinson's disease. Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-09-11 Lorenzo Gaetani,Federico Paolini Paoletti,Alessandro Mechelli,Giovanni Bellomo,Lucilla Parnetti
INTRODUCTION Diagnostic criteria for Parkinson's disease (PD) rely on clinical, mainly motor, features, implying that pre-motor phase cannot be accurately identified. To achieve a reliable early diagnosis, similar to what has been done for Alzheimer's disease (AD), a shift from clinical to biological identification of PD is being pursued. This shift has taken great advantage from the research on cerebrospinal
-
Implementing next-generation sequencing for diagnosis and management of hereditary hearing impairment: a comprehensive review Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-28 Cheng-Yu Tsai, Jacob Shu-Jui Hsu, Pei-Lung Chen, Chen-Chi Wu
Sensorineural hearing impairment (SNHI), a common childhood disorder with heterogeneous genetic causes, can lead to delayed language development and psychosocial problems. Next-generation sequencin...
-
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-28 Ugo Testa
Primary liver cancer is a major health problem being the sixth most frequent cancer in the world and the third cause of cancer-related death in the world. The most common histological type of liver...
-
A systematic review and meta-analysis combined with bioinformatic analysis on the predictive value of E-cadherin in patients with renal cell carcinoma Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-26 Zikuan Zhang, Bo Xue, Yongquan Chen, Yuan Shao, Dongwen Wang
Renal cell carcinoma (RCC) is the most common cancer of the kidney. This study aims to evaluate the potential predictive value of E-cadherin, a marker of the epithelial mesenchymal transit (EMT) pr...
-
Serum biomarkers for predicting microvascular complications of diabetes mellitus Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-19 Jiajia Wang, Xiaoyi Song, Ziqiao Xia, Shu Feng, Hangfeng Zhang, Chengjie Xu, Hui Zhang
Diabetic microvascular complications such as retinopathy, nephropathy, and neuropathy are primary causes of blindness, terminal renal failure, and neuropathic disorders in type 2 diabetes mellitus ...
-
Towards improved point-of-care (POC) testing for patients with suspected sepsis: POC tests for host biomarkers and possible microbial pathogens Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-13 Maria-Evangelia Adami, Evangelos J. Giamarellos-Bourboulis, Effie Polyzogopoulou
Sepsis is a heterogeneous syndrome often misdiagnosed. Point-of-care (POC) diagnostic tests are commonly used to guide decision and include host biomarkers and molecular diagnostics.The diagnostic ...
-
A review of the value of point-of-care testing for community-acquired pneumonia Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-12 Andrea Palomeque, Catia Cilloniz, Alba Soler-Comas, Joan Canseco-Ribas, Nona Rovira-Ribalta, Anna Motos, Antoni Torres
Community-acquired pneumonia (CAP) is an infectious disease associated with high mortality worldwide. Although Streptococcus pneumoniae remains the most frequent pathogen in CAP, data from recent s...
-
Clinical application of whole genome sequencing in young onset dementia: challenges and opportunities Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-12 Aamira Huq, Bryony Thompson, Ingrid Winship
Young onset dementia (YOD) by its nature is difficult to diagnose. Despite involvement of multidisciplinary neurogenetics services, patients with YOD and their families face significant diagnostic ...
-
Recent advances in CRISPR-Cas systems for colorectal cancer research and therapeutics Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-12 Saeideh Khorshid Sokhangouy, Farzaneh Alizadeh, Malihe Lotfi, Samaneh Sharif, Atefeh Ashouri, Yasamin Yoosefi, Saeed Bozorg Qomi, Mohammad Reza Abbaszadegan
Colon cancer, ranked as the fourth leading global cause of cancer death, exhibits a complex progression marked by genetic variations. Over the past decade, the utilization of diverse CRISPR systems...
-
Biomarkers of sleep-wake disturbance as predictors of cognitive decline and accelerated disease progression Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-11 Aren Tucker, Terry E. Goldberg, Hyun Kim
In older adults, where sleep disturbances and cognitive impairment are common, mounting evidence suggests a potential connection between sleep and cognitive function, highlighting the significance ...
-
The current clinical applications of preimplantation genetic testing (PGT): acknowledging the limitations of biology and technology Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-06 Georgia Kakourou, Christalena Sofocleous, Thalia Mamas, Christina Vrettou, Joanne Traeger-Synodinos
Preimplantation Genetic Testing (PGT) is a cutting-edge test used to detect genetic abnormalities in embryos fertilized through Medically Assisted Reproduction (MAR). PGT aims to ensure that embryo...
-
CYP19A1 polymorphisms and bladder cancer risk in the Chinese Han population Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-05 Jing Liang, Yongfei Li, Panpan Wan, Wenjing Zhang, Junhui Han, Man Zhang, Bin Li, Tianbo Jin
The expression of CYP19A1 has implications for the prognosis of female bladder cancer. However, this study aimed to explore the association between single nucleotide polymorphisms (SNPs) in CYP19A1...
-
An overview of early genetic predictors of IgA deficiency Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-08-01 Saba Fekrvand, Hassan Abolhassani, Nima Rezaei
Inborn errors of immunity (IEIs) refer to a heterogeneous category of diseases with defects in the number and/or function of components of the immune system. Immunoglobulin A (IgA) deficiency is th...
-
[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-25 Jessica Clore, Peter J.H. Scott
Theranostics targeting prostate-specific membrane antigen (PSMA) represent a new targeted approach for prostate cancer care that combines diagnostic and therapeutic radiopharmaceuticals to diagnose...
-
Interpreting the results of rapid molecular diagnostic tests for carbapenem-resistant Enterobacterales infection: current clinical perspective while waiting for further evidence Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-25 Daniele Roberto Giacobbe, Vincenzo Di Pilato, Antonio Vena, Anna Marchese, Matteo Bassetti
Carbapenem-resistant Enterobacterales (CRE) causing severe infections in humans have represented an important challenge for clinicians worldwide during the past two decades.Novel β-lactams and β-la...
-
The impact of next-generation sequencing for diagnosis and disease understanding of myeloid malignancies Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-25 Erica Vormittag-Nocito, Madina Sukhanova, Lucy A. Godley
Defining the chromosomal and molecular changes associated with myeloid neoplasms (MNs) optimizes clinical care through improved diagnosis, prognosis, treatment planning, and patient monitoring. Thi...
-
An overview of circulating and urinary biomarkers capable of predicting the transition of acute kidney injury to chronic kidney disease Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-15 Alexander E. Berezin, Tetiana A. Berezina, Uta C. Hoppe, Michael Lichtenauer, Alexander A. Berezin
Acute kidney injury (AKI) defined by a substantial decrease in kidney function within hours to days and is often irreversible with higher risk to chronic kidney disease (CKD) transition.The authors...
-
The role of fecal biomarkers in individuals with inflammatory bowel disease Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-12 Teagan S. Edwards, Andrew S. Day
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and Ulcerative Colitis (UC), is a relapsing and remitting condition. Noninvasive biomarkers have an increasingly important role i...
-
Point-of-care isothermal nucleic acid amplification tests: progress and bottlenecks for extraction-free sample collection and preparation Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-08 Alexis F. Wilkinson, Maria J. Barra, Emilie N. Novak, Meaghan Bond, Rebecca Richards-Kortum
Suitable sample collection and preparation methods are essential to enable nucleic acid amplification testing at the point of care (POC). Strategies that allow direct isothermal nucleic acid amplif...
-
Are we closer to robust predictors of recurrent pregnancy loss by means of integrating different types of omics data? Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-08 Yiqiu Wei, Zhimin Deng, Tailang Yin
Published in Expert Review of Molecular Diagnostics (Vol. 24, No. 7, 2024)
-
Correlation between lipoprotein-associated phospholipase A2 and poststroke mild cognitive impairment Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-07-03 Yawei Cao, Xiaofeng Zhu, Jin Shang, Jinlong Zheng, Xiangyang Tian, Qiu Han, Jun Shen
This study aimed to investigate the correlation between serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and poststroke mild cognitive impairment (PSMCI).The patients included in the study w...
-
Current status of diagnostic assays for emerging zoonotic viruses: Nipah and Hendra Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-06-26 Nancy Sharma, Vijay Lakshmi Jamwal, Sakshi Nagial, Manish Ranjan, Dharitri Rath, Sumit G. Gandhi
Nipah and Hendra viruses belong to the Paramyxoviridae family, which pose a significant threat to human health, with sporadic outbreaks causing severe morbidity and mortality. Early symptoms includ...
-
Metabolomics for searching validated biomarkers in cancer studies: a decade in review Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-06-21 Ángeles López-López, Ángeles López-Gonzálvez, Coral Barbas
In the dynamic landscape of modern healthcare, the ability to anticipate and diagnose diseases, particularly in cases where early treatment significantly impacts outcomes, is paramount. Cancer, a c...
-
A sandwich chemiluminescent magnetic microparticle immunoassay for cryptococcal antigen detection Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-06-19 Junpu Li, Yan Guo
Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. Cryptococcal antigen (CrAg) testing from serum and cerebrospinal fluid (CSF) has been regarded as a ...
-
Association between polymorphisms in TLR3, TICAM1 and IFNA1 genes and covid-19 severity in Southern Brazil Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-06-17 Matheus Braga, Mariana Akemi Sonoda Shiga, Pedro Emanuel Santiago Silva, Aléia Harumi Uchibaba Yamanaka, Victor Hugo Souza, Sergio Grava, Andréa Name Colado Simão, Janisleya Silva Ferreira Neves, Quirino Alves de Lima Neto, Joana Maira Valentini Zacarias, Jeane Eliete Laguila Visentainer
A distinct phenotype in Coronavirus disease 2019 (Covid-19) was observed in severe patients, consisting of a highly impaired interferon (IFN) type I response, an exacerbated inflammatory response.T...
-
Improving the diagnosis of tuberculosis: old and new laboratory tools Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-06-05 Priya Solanki, Linzy Elton, Isobella Honeyborne, Mirae Park, Giovanni Satta, Timothy D. McHugh
Despite recent advances in diagnostic technologies and new drugs becoming available, tuberculosis (TB) remains a major global health burden. If detected early, screened for drug resistance, and ful...
-
Cost analyses for malaria molecular diagnosis for research planners in India and beyond Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-20 Vandana Panwar, Shivani Bansal, Charu Chauhan, Abhinav Sinha
Malaria elimination mandates early and accurate diagnosis of infection. Although malaria diagnosis is programmatically dependent on microscopy/RDTs, molecular diagnosis has much better diagnostic a...
-
Association between NUDT17 polymorphisms and breast cancer risk Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-17 Junhui Han, Jing Liang, Wenqian Zhou, Man Zhang, Tianbo Jin
Breast cancer (BC) is the leading cause of cancer death among women worldwide. The nudix hydrolase 17 (NUDT17) may play notable roles in cancer growth and metastasis. In this study, we explored the...
-
Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-17 Dina Yehia, Clarus Leung, Don D. Sin
Chronic obstructive pulmonary disease (COPD) accounts for 545 million people living with chronic respiratory disorders and is the third leading cause of morbidity and mortality around the world. CO...
-
Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-16 Matt Evans, Timothy Kendall
Advances in precision medicine have expanded access to targeted therapies and demand for molecular profiling of cholangiocarcinoma (CCA) patients in routine clinical practice. However, pathologists...
-
Sample-to-result molecular diagnostic platforms and their suitability for infectious disease testing in low- and middle-income countries Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-15 Anne Hauner, Chukwuemeka Onwuchekwa, Kevin K. Ariën
Diagnostics are an essential, undervalued part of the health-care system. For many diseases, molecular diagnostics are the gold standard, but are not easy to implement in Low- and Middle-Income Cou...
-
Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-13 Gabriele Roccuzzo, Cristina Sarda, Valentina Pala, Simone Ribero, Pietro Quaglino
Over the past decade, significant advancements in the field of melanoma have included the introduction of a new staging system and the development of immunotherapy and targeted therapies, leading t...
-
A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-11 Mingze Guan, Hua Zhao, Qi Zhang, Li Li, Xiaobo Wang, Bo Tang
Although anoikis plays a role in cancer metastasis and aggressiveness, it has rarely been reported in diffuse large B cell lymphoma (DLBCL).We obtained RNA sequencing data and matched clinical data...
-
Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-09 Christine McCaffrey, Chowdhury Jahangir, Clodagh Murphy, Caoimbhe Burke, William M. Gallagher, Arman Rahman
Histological images contain phenotypic information predictive of patient outcomes. Due to the heavy workload of pathologists, the time-consuming nature of quantitatively assessing histological feat...
-
Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-05-06 Calogero Ciulla, Claudio Luchini
A marked histomolecular heterogeneity characterizes pancreatic cancer. Thus, different tumor histologies with divergent genomic profiles exist within the same category.Using data from PubMed, SCOPU...
-
The emerging role of liquid biopsy in oral squamous cell carcinoma detection: advantages and challenges Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-04-12 Sudha Gupta, Brijesh Singh, Rajul Abhishek, Sameer Gupta, Manisha Sachan
Oral Squamous Cell Carcinoma (OSCC), the sixth most widespread malignancy in the world, accounts for 90% of all cases of oral cancer. The primary risk factors are tobacco chewing, alcohol consumpti...
-
Body fluid markers for multiple sclerosis and differential diagnosis from atypical demyelinating disorders Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-03-27 Angelika Bauer, Harald Hegen, Markus Reindl
Body fluid markers could be helpful to predict the conversion into clinically definite multiple sclerosis (MS) in people with a first demyelinating event of the central nervous system (CNS). Conseq...
-
A state-of-the-art overview of candidate diagnostic biomarkers for Attention-deficit/hyperactivity disorder (ADHD) Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-03-26 Valeria Parlatini, Alessio Bellato, Alessandra Gabellone, Lucia Margari, Lucia Marzulli, Emilia Matera, Maria Giuseppina Petruzzelli, Marco Solmi, Christoph U. Correll, Samuele Cortese
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental conditions and is highly heterogeneous in terms of symptom profile, associated cognitive deficits, comor...
-
Performance of noninvasive prenatal screening for fetal sex chromosome aneuploidies in a cohort of 116,862 pregnancies Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-03-25 Yanfei Xu, Jianbo Lou, Yeqing Qian, Pengzhen Jin, Yangwen Qian, Jiawei Hong, Yuqing Xu, Yixuan Yin, Songjia Yi, Minyue Dong
Noninvasive prenatal screening (NIPS) has shown good performance in screening common aneuploidies. However, its performance in detecting fetal sex chromosome aneuploidies (SCAs) needs to be evaluat...
-
Opportunities and challenges of point of care testing paradigms in the post-COVID era Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-03-19 Barbara Van Der Pol
Published in Expert Review of Molecular Diagnostics (Vol. 24, No. 3, 2024)
-
PCR diagnostic platforms for non-Aspergillus mold infections: ready for routine implementation in the clinic? Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-03-19 Frederic Lamoth, Dimitrios P. Kontoyiannis
While Aspergillus spp. remain the predominant cause of invasive mold infections, non-Aspergillus molds, such as the Mucorales or Fusarium spp., account for an increasing proportion of cases. The di...
-
An overview of point-of-care testing for infections in critically ill patients Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-27 Alena Moerman, Jan J. De Waele, Jerina Boelens
Molecular diagnostic systems for point-of-care (POC) testing are nowadays routinely used and are part of many labs. Although often intended for bedside use outside of the microbiology lab, there is...
-
Detection of lung cancer and stages via breath analysis using a self-made electronic nose device Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-19 Binson V A, Philip Mathew, Sania Thomas, Luke Mathew
Breathomics is an emerging area focusing on monitoring and diagnosing pulmonary diseases, especially lung cancer. This research aims to employ metabolomic methods to create a breathprint in human-e...
-
The diagnosis of central nervous system infections in resource-limited settings and the use of novel and molecular diagnostic platforms to improve diagnosis Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-19 James Milburn, Rachita Suresh, Ronan Doyle, Joseph N Jarvis
Central nervous system infections (CNSI) disproportionately affect individuals in low-resource settings where diagnosis is challenging; large proportions of patients never receive a confirmed micro...
-
From biochemical markers to molecular endotypes of osteoarthritis: a review on validated biomarkers Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-14 Monica T. Hannani, Christian S. Thudium, Morten A. Karsdal, Christoph Ladel, Ali Mobasheri, Melanie Uebelhoer, Jonathan Larkin, Jaume Bacardit, André Struglics, Anne-Christine Bay-Jensen
Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated ...
-
Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-14 Matthew Spinelli, Monica Gandhi
Although effective antiretroviral and pre-exposure prophylaxis/PrEP regimens are available globally, adherence challenges persist. Objective measures of adherence can both measure adherence accurat...
-
The impact of companion diagnostic testing on medical decision making and IVD regulations Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-12 Jan Trøst Jørgensen
Published in Expert Review of Molecular Diagnostics (Ahead of Print, 2024)
-
Fast detection of bacterial gut pathogens on miniaturized devices: an overview Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-13 Gratiela Gradisteanu Pircalabioru, Mina Raileanu, Mihai Viorel Dionisie, Irina-Oana Lixandru-Petre, Ciprian Iliescu
Gut microbes pose challenges like colon inflammation, deadly diarrhea, antimicrobial resistance dissemination, and chronic disease onset. Development of early, rapid and specific diagnosis tools is...
-
Polymerase Spiral Reaction (PSR) as a point-of-care diagnostic assay: A systematic review Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-09 Rashi Dixit, Naveen Kumar Kodali, Manisha Biswal, John Antony Jude Prakash, Natarajan Gopalan, Padma Das, Sujit Kumar Behera
The current systematic review aimed to collect and analyze the comprehensive evidence regarding Polymerase Spiral Reaction (PSR) and to estimate its diagnostic performance and usefulness as a point...
-
Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-09 Gabriele Roccuzzo, Eleonora Bongiovanni, Luca Tonella, Valentina Pala, Sara Marchisio, Alessia Ricci, Rebecca Senetta, Luca Bertero, Simone Ribero, Enrico Berrino, Caterina Marchiò, Anna Sapino, Pietro Quaglino, Paola Cassoni
Over the past two years, the scientific community has witnessed an exponential growth in research focused on identifying prognostic biomarkers for melanoma, both in pre-clinical and clinical settin...
-
Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-02-05 Gracia Maria Vargas, Neha Shafique, Xiaowei Xu, Giorgos Karakousis
Tumor-infiltrating lymphocytes (TILs) have been investigated as prognostic factors in melanoma. Recent advancements in assessing the tumor microenvironment in the setting of more widespread use of ...
-
The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-31 Firas Kobeissy, Rawad Daniel Arja, Jennifer C. Munoz, Deborah A. Shear, Janice Gilsdorf, Jiepei Zhu, Hamad Yadikar, William Haskins, J. Adrian Tyndall, Kevin K. Wang
Major organ-based in vitro diagnostic (IVD) tests like ALT/AST for the liver and cardiac troponins for the heart are established, but an approved IVD blood test for the brain has been missing, high...
-
Multi-omics and single-cell sequencing analyses reveal the potential significance of circadian pathways in cancer therapy Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-30 Hao Lai, Xiaoyun Xiang, Xingqing Long, Zuyuan Chen, Yanling Liu, Xiaoliang Huang
Circadian rhythm disturbance is an independent risk factor for cancer. However, few studies have been reported on circadian rhythm related genes (CRGs) in cancer, so it is important to further expl...
-
SOWAHB polymorphisms affect thyroid cancer risk in the Chinese Han population Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-23 Man Zhang, Jing Liang, Junhui Han, Wenjing Zhang, Panpan Wan, Leteng Yang, Xufeng Zang, Wanli Ren, Ling Zhang, Hao Dai, Yue Wu, Tianbo Jin
This study aimed to detect the correlation between SOWAHB polymorphisms and Thyroid cancer (TC) risk in the Chinese Han population.We genotyped SOWAHB variants in 510 TC patients and 509 controls u...
-
Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-22 Maureen Sampson, Anna Wolska, Rafael Zubiran, Justine Cole, Marcelo Amar, Alan T. Remaley
Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4–6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk.Usin...
-
Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the IdyllaTM platform: a real-world two-center experience in Greece Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-11 Kleita Michaelidou, Ioannis Karniadakis, Varvara Pantelaion, Chara Koutoulaki, Eleni Boukla, Konstantinos Folinas, Pantelis Dimaras, Maria A Papadaki, Anastasios V Koutsopoulos, Dimitrios Mavroudis, Christine Vourlakou, Konstantinos Mavridis, Sofia Agelaki
Limited information exists on epidermal growth factor receptor (EGFR) molecular epidemiology in Greece. Next-generation sequencing (NGS) is the recommended method for EGFR genotyping in NSCLC. The ...
-
Molecular biomarkers of diffuse axonal injury: recent advances and future perspectives Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-11 Youyou Zhang, Zhaoyang Li, Hui Wang, Zhiyong Pei, Shuquan Zhao
Diffuse axonal injury (DAI), with high mortality and morbidity both in children and adults, is one of the most severe pathological consequences of traumatic brain injury. Currently, clinical diagno...
-
Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-05 Shi-Ping Yang, Ke Liu, Yang Li, Guan-Qiao Li, Jia-Yi Li, Yu-Yi Lin, San-Gang Wu
Limited data exist regarding the utility and validity of the 21-gene recurrence score (RS) in patients with de novo metastatic breast cancer (dnMBC). This study aimed to investigate the practice pa...
-
We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what? Expert Rev. Mol. Diagn. (IF 3.9) Pub Date : 2024-01-04 Jason Grebely, Susan Matthews, Louise M. Causer, Jordan J. Feld, Philip Cunningham, Gregory J. Dore, Tanya L. Applegate
Progress toward hepatitis C virus (HCV) elimination is impeded by low testing and treatment due to the current diagnostic pathway requiring multiple visits leading to loss to follow-up. Point-of-ca...